Table 1 Overview of the study patients’ characteristics
| Â | AML patients analyzed for IDH mutations | P-value | ||
|---|---|---|---|---|
n = 3234 | ||||
IDHWT | IDH1mut | IDH2mut | ||
n = 2638 | n = 253 | n = 353 | ||
Age (years), median (IQR) | 51 (40–59) | 54 (44–62) | 55 (47–62) | < .001 |
Sex, n/N (%) | .845 | |||
 Female | 1312/2638 (49.7) | 130/253 (51.4) | 179/353 (50.7) | |
 Male | 1326/2638 (50.3) | 123/253 (48.6) | 174/353 (49.3) | |
Disease status, n/N (%) | .082 | |||
 De novo | 2238/2622 (85.4) | 228/252 (90.5) | 304/353 (86.1) | |
 sAML | 255/2622 (9.7) | 21/252 (8.3) | 34/353 (9.6) | |
 t-AML | 129/2622 (4.9) | 3/252 (1.2) | 15/353 (4.2) | |
 Hb (mmol/l), median (IQR) | 5.71 (4.9–6.7) | 5.65 (5.1–6.6) | 5.84 (5–6.8) | .215 |
 Platelets (Gpt/L), median (IQR) | 51 (28–95) | 71 (36–126) | 72 (41–147) | < .001 |
 WBC (Gpt/L), median (IQR) | 14.98 (3.9–49.1) | 12.51 (2.6–44.2) | 12.6 (2.8–45.3) | .824 |
 Bone marrow blasts (%), median (IQR) | 63 (40–80) | 73 (54–88) | 70 (44–83) | < .001 |
 Peripheral blasts (%), median (IQR) | 27 (7–63) | 50 (15–81) | 36 (9–70) | < .001 |
 LDH (U/L), median (IQR) | 430 (273–760.8) | 425.4 (261–762) | 368 (236–624) | .012 |
 Complex karyotype, n/N (%) | 258/2532 (10.2) | 4/235 (1.7) | 14/336 (4.2) | < .001 |
ELN risk 2017, n/N (%) | < .001 | |||
 Favorable | 998/2462 (40.5) | 117/227 (51.5) | 132/332 (39.8) | |
 Intermediate | 886/2462 (36) | 89/227 (39.2) | 132/332 (39.8) | |
 Adverse | 578/2462 (23.5) | 21/227 (9.3) | 68/332 (20.5) | |
 NPM1 mut, n/N (%) | 840/2621 (32) | 149/252 (59.1) | 160 (45.3) | < .001 |
 FLT3-ITD mut, n/N (%) | 629/2630 (23.9) | 55/252 (21.8) | 82/353 (23.2) | .741 |
 CEBPA mut, n/N (%) | 220/2595 (8.5) | 3/253 (1.2) | 18/351 (5.2) | < .001 |
 IDH1 mut, n/N (%) | 0/2638 (0) | 253/253 (100) | 10/353 (2.8) |  |
 R132C | – | 92/253 (36.4) | 1/10 (10) | |
 R132G | – | 17/253 (6.7) | 1/10 (10) | |
 R132H | – | 118/253 (46.6) | 8/10 (80) | |
 R132L | – | 12/253 (4.7) | – | |
 R132S | – | 14/253 (5.5) | – | |
IDH2 mut, n/N (%) | 0/2638 (0) | 10/253 (4) | 353/353 (100) | Â |
 R140G | – | – | 1/351 (0.3) | |
 R140L | – | – | 6/351 (1.7) | |
 R140Q | – | 10/10 (100) | 269/351 (76.6) | |
 R140 W | – | – | 4/351 (1.1) | |
 R172K | – | – | 68/351 (19.4) | |
 R172S | – | – | 1/351 (0.3) | |
 V161L | – | – | 1/351 (0.3) | |
 WT | – | – | 1/351 (0.3) | |
 IDH1 and IDH2 mut, n/N (%) | 0/2638 (0) | 10/253 (4) | 10/353 (3) |  |
 IDH VAF (%), median (IQR) | – | 39 (26.2–43.2) | 38.1 (31.7–43.6) | .252 |
 alloHCT in CR1, n/N (%) | 714/2638 (27.1) | 53/253 (20.9) | 85/353 (24.1) | .066 |